Gapping up
In reaction to strong earnings/guidance:
- PRGS +24.2%, SAIC +11.6%, BB +6.5%, KMX +4.3%, BGCP +2.1%, HYRE +0.8%
Other news:
- GLPG +14.4% (Galapagos NV and Gilead announce that filgotinib met primary and key secondary endpoints in the Phase 3 FINCH 1 study)
- EXP +7.7% (Sachem affirms 8.9% active stake; intends to engage in discussions with management, board, and other stockholders )
- SGMO +4.9% (presents new preclinical data demonstrating significant (>80%) reduction of tau expression in the nonhuman primate brain following administration of zinc finger protein transcription factors)
- AXGT +3.6% (provides updates and plans regarding AXO-AAV-GM2 and AXO-Lenti-PD programs)
- GILD +2.8% (Galapagos NV and Gilead announce that filgotinib met primary and key secondary endpoints in the Phase 3 FINCH 1 study)
- REV +2.4% (files previously delayed 10-K and discloses material weakness in the internal control over financial reporting)
- WFC +2.1% (announces retirement of CEO Timothy J. Sloan, effective June 30; appoints C. Allen Parker as Interim CEO, effective immediately)
- ALGN +1.7% (Align Tech to receive $35 mln from Straumann to settle ClearCorrect patent disputes and signs letter of intent for Straumann to distribute iTero scanners), AMRN +1.7% (submits sNDA to FDA seeking new indication for Vascepa to reduce the risk of major adverse cardiovascular events)
- MS +0.9% (confirms President Colm Kelleher plans to retire effective June 30, 2019)
Analyst comments:
- TGTX +6% (initiated with an Overweight at Cantor Fitzgerald)
- VKTX +4.2% (upgraded to Outperform from Mkt Perform at SVB Leerink)
- APLS +1.9% (initiated with Outperform at Robert W. Baird)